Shao Li is a tenured professor and the director of Institute of TCM-X at Tsinghua University. He is the member of European Academy of Sciences and Arts, the Fellow of the Royal Society of Chemistry, and the Fellow of the Royal Society of Biology. He is also the founder and Chairman of Specialty Committee of Network Pharmacology, World Federation of Chinese Medicine Societies, and Specialty Committee of Biomedical Big Data, Chinese Society of Bioengineering. He proposed the “network target” concept and methodology to shift the “one target, one drug” approach, and is exploring a new way to the network-based precision Chinese Medicine on inflammation and cancer. He led the first international standard of network pharmacology, and published 200+ papers, which have been cited 11400+ times. He held over 30 US and China patents. He was honored the 1st Prize of International Award for Contribution to Chinese Medicine, Li Shizhen Pharmaceutical Innovation Award, Leading talents of National Ten-Thousand Talents Program, National Science Fund for Distinguished Young Scholars, National Science & Technology Award, National Education Award, and National Excellent Doctoral Dissertation. He was selected in 2019/2020/2021/2022/2023 World’s Top 2% Scientists, and 2021/2022/2023 Highly Cited Chinese Researchers (Elsevier).